Drug-induced Pneumonitis Following the Administration of TAS-102

Drug-induced Pneumonitis Following the Administration of TAS-102

A 59-year-old woman, diagnosed with advanced rectal cancer, presented with a low-grade fever and dyspnea on exertion after the 2nd cycle of TAS-102. TAS-102 has promising efficacy in patients with metastatic colorectal cancer. A CT scan revealed mosaic patterns with bilateral ground-glass opacities. The drug lymphocyte stimulation test for TAS-102 was strongly positive and serum β-D glucan leve...

Difference in Neutropenia due to Administration Schedule of TAS-102

TAS-102 significantly improves overall survival in patients with metastatic colorectal cancer. The most common adverse event of TAS-102 is bone marrow suppression, which leads to neutropenia. The incidence of neutropenia is high, and there is no known effective prevention method. Furthermore, the administration method of TAS-102 is complicated. We reported that neutropenia could be avoided by c...

TAS-102 and the quest for predictive biomarkers

Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

BACKGROUND Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients. METHODS In this double-blind study, we randomly ass...

Trichosporon beigelii pneumonitis following busulphan-induced leucopenia.

We present a 41 yr old male, who died of respiratory failure due to infiltration of Trichosporon beigelii (cutaneum) into the pulmonary interstitial spaces with systemic dissemination. Busulphan-induced leucopenia in the chronic phase of chronic myelogenous leukaemia had progressed before this infection developed. In leukaemic patients with profound leucopenia, interstitial pneumonitis due to T...